Q1 2026 preliminary EPS beat; Q2 previews mixed
Key Questions
What were PepsiCo's Q1 2026 preliminary EPS results?
PepsiCo reported Q1 2026 preliminary EPS of $2.26, beating estimates of $2.24 by 0.89% and up 15% year-over-year. It holds a Zacks #3 rank and is a Dividend King with 13% 12-week expected capital appreciation.
How did PepsiCo's Q1 2026 revenue perform against expectations?
Revenue came in at $29.34 billion, surpassing estimates of $28.97 billion, driven by strong EMEA performance. ROE stood at 43.53%, with the earnings call scheduled for April 16.
What is Zacks' preview for PepsiCo's Q2 2026 earnings?
Zacks previews Q2 EPS at $1.55 and revenue at $18.95 billion. Full-year 2026 estimates are $8.62 EPS and $98.19 billion in revenue.
What is UBS's latest rating and price target for PepsiCo?
UBS maintains a Buy rating but lowered its price target to $186 from $190 due to H2 inflation risks. This reflects mixed previews amid brand rebounds like Lay’s and Doritos.
What is PepsiCo's stock performance year-to-date?
PepsiCo's stock is at $152.76, resilient and up 10% YTD. It trades amid a price target range of $140-193, considered undervalued at $153-269.
What risks are highlighted for PepsiCo ahead of earnings?
Risks include North America challenges, GLP-1 impacts, PFNA turnaround, Middle East issues, and H2 inflation. BofA notes mixed PBNA results and lags in Tostitos.
How does PepsiCo compare to peers like KDP and Coca-Cola?
KDP tops PepsiCo on valuation (P/OpInc) in soft drinks, per Trefis. KO serves as a comparable amid PepsiCo's resilience and turnaround efforts.
What is the range of analyst price targets for PepsiCo?
Price targets range from $140 to $193, with some views up to $269 indicating undervaluation. Factors include NA recovery, GLP-1 headwinds, and brand resets.
Q1 EPS $2.26 vs $2.24 est (0.89% beat/15% YoY/Zacks #3, Dividend King, 13% 12wk ECAP), rev $29.34B vs $28.97B (EMEA strong), ROE 43.53%; April 16 call. BofA in-line Q1 $1.53 EPS/$8.60 FY26/FNA reset signs (Lay’s/Ruffles/Doritos rebound/Tostitos lag), PBNA mixed, ME risks; UBS Buy $186 (trim from $190, H2 inflation risks); Zacks Q2 $1.55/$18.95B/FY $8.62/98.19B; stock $152.76 resilient/YTD +10%; PTs $140-193/underval $153-269 amid NA/GLP-1/PFNA/turnaround; KO comps.